Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion

Heslin, Margaret; Patel, Anita; Stahl, Daniel; Gardner-Sood, Poonam; Mushore, Manyara; Smith, Shubulade; Greenwood, Kathryn; Onagbesan, Oluwadamilola; O’Brien, Conan; Fung, Catherine; Ohlsen, Ruth; Hopkins, David; Lowe, Philippa; Arbuthnot, Maurice; Mutatsa, Stan; Todd, Gill; Kolliakou, Anna; Lally, John; Stubbs, Brendon; Ismail, Khalida; David, Anthony; Murray, Robin; Atakan, Zerrin; Gaughran, Fiona

doi:10.1186/s12888-017-1570-1

Table 3 Costs at baseline, 12 and 15 months (2011/12 prices, all 15 month costs, except the intervention costs, are discounted)

From: Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion

		Intervention n = 213			Control n = 193		Unadjusted mean difference^d	95% CI^d	Adjusted mean difference^e	95% CI^e
	valid n	Mean £	SD	valid n	Mean £	SD
Component Costs at Baseline
Health & social care excluding intervention^b	212	10,242	13,374	193	9714	13,767	528	−2953 to 4010	967	−2442 to 4435
Charity^b	212	83	611	193	80	435	3	−109 to 115	−22	−137 to 94
Lost productivity^b	212	8755	5964	193	7472	6311	1283	−354 to 2920	456	−894 to 1806
Patient^b	212	72	433	193	188	188	35	−31 to 102	33	−37 to 104
Benefits^b	212	2211	1006	193	2009	940	202^a	13 to 391^a	127	−70 to 324
Component Costs at 12 month
Health & social care excluding intervention^b	160	10,220	12,341	159	10,196	16,987	24	−4219 to 4267	−1596	−5145 to 1954
Charity^b	160	120	369	159	61	256	60	−6 to 125	80^a	9 to 151^a
Lost productivity^b	160	8882	5998	159	7707	6333	1174	−317 to 2665	1038	−367 to 2443
Patient^b	160	84	369	159	53	300	31	−38 to 100	25	−46 to 96
Benefit^b	160	2328	931	159	2129	957	200	−14 to 413	87	−105 to 279
Component Costs at 15 month
Health & social care excluding intervention^c	152	4874	6317	149	4708	6383	166	−1577 to 1910	−231	−1734 to 1272
Charity^c	152	63	215	149	49	230	14	−39 to 67	24	−37 to 84
Lost productivity^c	152	4731	2674	149	3880	3027	850^a	127 to 1573^a	608	−25 to 1240
Patient^c	152	24	141	149	30	162	−6	−38 to 27	−6	−37 to 25
Benefits^c	152	1089	439	149	1049	441	40	−70 to 150	−24	−125 to 76
Intervention	213	316	173	193	4	0	312^a	267 to 357^a	3142^a	268 to 359^a
Total Costs at 15 months
Health & social care including intervention^f	152	5209	6326	149	4711	6383	498	−1248 to 2244	95	−1410 to 1599
Societal perspective including intervention^f	152	11,116	7271	149	9720	7707	1396	−684 to 3476	675	−1039 to 2388

All figures are rounded to nearest whole number
^aConfidence interval excludes zero
^bCosts for a 6 month retrospective period
^cCosts for a 3 month retrospective period
^dAdjusting for clustering of care coordinator only
^eIncludes covariates for baseline: equivalent cost, SF-36 mental component score, SF-36 physical component score, EQ-5D-3 L utility, SF-36 utility, gender, ethnicity and borough, plus clustering for care coordinator
^fFifteen month costs discounted

Back to article page

ISSN: 1471-244X

Contact us

Submission enquiries: bmcpsychiatry@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Psychiatry

Contact us